Welcome to our dedicated page for Savara SEC filings (Ticker: SVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phase-3 trial data scattered across hundreds of pages feels daunting when all you really want to know is whether Savara’s cash runway can carry Aerovanc and molgramostim to the next milestone. Biotech reports are dense with technical jargon and milestone-driven accounting quirks that hide critical signals. Our dedicated Savara SEC filings hub tackles that complexity head-on.
Stock Titan’s AI reads every Savara quarterly earnings report 10-Q filing, annual report 10-K, and 8-K material event the moment EDGAR posts them, then translates the findings into clear language. Need Savara insider trading Form 4 transactions before the bell? You’ll see Form 4 insider transactions real-time, complete with context around each executive stock move. Trying to understand clinical spend trends or dilution risk? Our AI summaries highlight the exact pages so understanding Savara SEC documents with AI becomes effortless.
All filing types are covered:
- Savara executive stock transactions Form 4
- Savara proxy statement executive compensation insights
- Savara earnings report filing analysis with visualized KPIs
- Savara 8-K material events explained for trial outcomes
Frazier-affiliated investment vehicles disclosed shared voting and dispositive power over specified Savara Inc. (SVRA) common stock positions. Frazier Life Sciences Public Fund, L.P. directly holds 6,745,296 shares (3.9%); Frazier Life Sciences Public Overage Fund, L.P. holds 2,889,469 shares (1.7%); Frazier Life Sciences X, L.P. holds 324,346 shares (0.2%); and Frazier Life Sciences XI, L.P. holds 1,503,190 shares (0.9%). These percentages are calculated using 172,836,922 shares outstanding as reported by the issuer. The filing clarifies that certain investment committees act by majority vote and explicitly corrects prior attributions of beneficial ownership to individual committee members.
Savara Inc. reported widening losses as it advances its sole product candidate, MOLBREEVI, an inhaled GM-CSF for autoimmune pulmonary alveolar proteinosis. Net loss was $30.4 million for the quarter and $57.0 million for the six months, up from $22.2 million and $42.6 million a year earlier, driven by higher research-and-development and commercial-preparation costs.
The company holds $17.4 million in cash and $129.0 million in short-term investments (total ~$146.4 million) and states this is sufficient to fund operations for at least the next 12 months. Savara received an FDA Refusal to File for its BLA but says the RTF raised CMC information requests only, not safety or efficacy; the company plans a December resubmission and will request Priority Review. Savara has a $200 million Hercules term loan facility with an initial $30 million draw, conditional future tranches tied to regulatory and revenue milestones and covenanted cash requirements that could restrict liquidity.
Schedule 13G filing for Savara Inc. (SVRA) shows that a group of Venrock Healthcare Capital Partners funds and related managers/individuals has crossed the 5% disclosure threshold.
- Reporting group: Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, and principals Nimish Shah and Bong Y. Koh.
- Aggregate beneficial ownership: 9,021,507 common shares.
- Ownership breakdown: 1,997,410 shares (VHCP III); 199,772 shares (VHCP Co-Investment III); 6,824,325 shares (VHCP EG).
- Percentage of class: 5.2% of Savara’s 172,836,922 outstanding shares (as of 13 May 2025).
- Voting & dispositive power: 0 shares sole; 9,021,507 shares shared—indicating coordinated but passive ownership. Filing is under Rule 13d-1(c), not 13D, so the group states no intent to influence control.
- Date of event triggering filing: 30 June 2025; filing signed 08 July 2025.
The disclosure signals that Venrock, a life-science–focused investor, holds a meaningful but non-controlling position in Savara. Investors often view recognized sector specialists taking a >5% stake as a vote of confidence, yet the filing itself does not imply any change in Savara’s strategy, capital structure, or governance. The stake is passive and therefore has limited immediate operational impact.
FAQ
What is the current stock price of Savara (SVRA)?
What is the market cap of Savara (SVRA)?
